世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
非副腎皮質ステロイド性免疫調節薬の世界市場シェアとランキング、全体売上高と需要予測 2024-2030Non-corticosteroid lmmunomodulators - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030 非副腎皮質ステロイド性免疫調節薬の世界市場は、2023年に100万米ドルの価値があると推定され、2024年から2030年の予測期間中に％のCAGRで2030年までに100万米ドルの再調整された規模になると予測されています。 ... もっと見る
※当ページの内容はウェブ更新時の情報です。 
サマリー非副腎皮質ステロイド性免疫調節薬の世界市場は、2023年に100万米ドルの価値があると推定され、2024年から2030年の予測期間中に％のCAGRで2030年までに100万米ドルの再調整された規模になると予測されています。非副腎皮質ステロイド免疫調節薬の北米市場は、2023年に百万ドルと評価され、2024年から2030年の予測期間中に％のCAGRで、2030年までに百万ドルに達すると予測されています。 非副腎皮質ステロイド免疫調節薬のアジア太平洋市場は、2023年に100万ドルと評価され、2024年から2030年の予測期間中に％のCAGRで、2030年までに100万ドルに達するだろう。 非副腎皮質ステロイド性免疫調節薬のヨーロッパ市場は、2023年に100万ドルと評価され、2024年から2030年の予測期間中に％のCAGRで、2030年までに100万ドルに達するだろう。 非副腎皮質ステロイド性免疫調節薬の世界的な主要企業は、アコードヘルスケア、ブリストル-マイヤーズスクイブカンパニー、アステラファーマ、ジェンザイム株式会社、グラクソ・スミスクラインPLC、メルクKGaA、F.Hoffmann-La Roche AG、GlenmarkPharmaceuticals、およびファイザー株式会社などが含まれます。2023年には、世界の大手5社が売上高で約 %のシェアを占めています。 レポートの範囲 本レポートは、非副腎皮質ステロイド性免疫調節薬の世界市場を包括的に紹介することを目的としており、地域別・国別、タイプ別、用途別の非副腎皮質ステロイド性免疫調節薬の分析とともに、総売上高、主要企業の市場シェア、ランキングに焦点を当てています。 非副腎皮質ステロイド性免疫調節薬の市場規模、推計、予測は、2023年を基準年とし、2019年から2030年までの期間の履歴データと予測データを売上高（百万ドル）で提供しています。量的および質的分析により、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場での地位を分析し、非副腎皮質ステロイド免疫調節薬に関する情報に基づいたビジネス上の意思決定を行うのに役立ちます。 市場区分 企業別 アコードヘルスケア ブリストル・マイヤーズ スクイブ社 アステラ・ファーマ ジェンザイム グラクソ・スミスクラインPLC メルクKGaA エフ・ホフマン・ラ・ロシュAG グレンマーク医薬品株式会社 ファイザー マイラン・ラボラトリーズInc. アクタビス ノバルティスAG ユダス・カディラ タイプ別セグメント カルシニューリン阻害剤 抗増殖剤 mTOR阻害剤 IMDH阻害剤 その他 用途別セグメント 臓器移植 アトピー性皮膚炎 その他 地域別 北米 米国 カナダ 欧州 ドイツ フランス 英国 イタリア ロシア アジア太平洋 中国 日本 韓国 中国 台湾 東南アジア インド ラテンアメリカ メキシコ ブラジル アルゼンチン 中東・アフリカ トルコ サウジアラビア アラブ首長国連邦 各章の概要 第1章： レポートのスコープ、世界の総市場規模を紹介。本章ではまた、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。 第2章：非副腎皮質ステロイド性免疫調節薬メーカーの競争環境、収益市場シェア、最新の開発計画、合併・買収情報などを詳細に分析。 第3章：各種市場セグメントをタイプ別に分析し、各市場セグメントの市場規模や発展可能性を網羅し、読者が各市場セグメントにおけるブルーオーシャン市場を見つけやすくします。 第4章：用途別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる下流市場のブルーオーシャン市場を見つけるのに役立ちます。 第5章：地域レベルでの非副腎皮質ステロイド性免疫調節薬の収益。各地域の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、将来の発展展望、市場空間、市場規模を紹介しています。 第6章 国別非副腎皮質ステロイド性免疫調節薬の収益。各国・地域のタイプ別、用途別のシグメイトデータを提供。 第7章：主要企業のプロファイルを提供し、製品収益、売上総利益率、製品紹介、最近の開発など、市場における主要企業の基本的な状況を詳細に紹介する。 第8章：産業の上流と下流を含む産業チェーンの分析。 第9章：結論 目次1 Market Overview1.1 Non-corticosteroid lmmunomodulators Product Introduction 1.2 Global Non-corticosteroid lmmunomodulators Market Size Forecast 1.3 Non-corticosteroid lmmunomodulators Market Trends & Drivers 1.3.1 Non-corticosteroid lmmunomodulators Industry Trends 1.3.2 Non-corticosteroid lmmunomodulators Market Drivers & Opportunity 1.3.3 Non-corticosteroid lmmunomodulators Market Challenges 1.3.4 Non-corticosteroid lmmunomodulators Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Non-corticosteroid lmmunomodulators Players Revenue Ranking (2023) 2.2 Global Non-corticosteroid lmmunomodulators Revenue by Company (2019-2024) 2.3 Key Companies Non-corticosteroid lmmunomodulators Manufacturing Base Distribution and Headquarters 2.4 Key Companies Non-corticosteroid lmmunomodulators Product Offered 2.5 Key Companies Time to Begin Mass Production of Non-corticosteroid lmmunomodulators 2.6 Non-corticosteroid lmmunomodulators Market Competitive Analysis 2.6.1 Non-corticosteroid lmmunomodulators Market Concentration Rate (2019-2024) 2.6.2 Global 5 and 10 Largest Companies by Non-corticosteroid lmmunomodulators Revenue in 2023 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-corticosteroid lmmunomodulators as of 2023) 2.7 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Calcineurin Inhibitors 3.1.2 Antiproliferative Agents 3.1.3 mTOR Inhibitors 3.1.4 IMDH Inhibitors 3.1.5 Others 3.2 Global Non-corticosteroid lmmunomodulators Sales Value by Type 3.2.1 Global Non-corticosteroid lmmunomodulators Sales Value by Type (2019 VS 2023 VS 2030) 3.2.2 Global Non-corticosteroid lmmunomodulators Sales Value, by Type (2019-2030) 3.2.3 Global Non-corticosteroid lmmunomodulators Sales Value, by Type (%) (2019-2030) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Organ Transplant 4.1.2 Atopic Dermatitis 4.1.3 Others 4.2 Global Non-corticosteroid lmmunomodulators Sales Value by Application 4.2.1 Global Non-corticosteroid lmmunomodulators Sales Value by Application (2019 VS 2023 VS 2030) 4.2.2 Global Non-corticosteroid lmmunomodulators Sales Value, by Application (2019-2030) 4.2.3 Global Non-corticosteroid lmmunomodulators Sales Value, by Application (%) (2019-2030) 5 Segmentation by Region 5.1 Global Non-corticosteroid lmmunomodulators Sales Value by Region 5.1.1 Global Non-corticosteroid lmmunomodulators Sales Value by Region: 2019 VS 2023 VS 2030 5.1.2 Global Non-corticosteroid lmmunomodulators Sales Value by Region (2019-2024) 5.1.3 Global Non-corticosteroid lmmunomodulators Sales Value by Region (2025-2030) 5.1.4 Global Non-corticosteroid lmmunomodulators Sales Value by Region (%), (2019-2030) 5.2 North America 5.2.1 North America Non-corticosteroid lmmunomodulators Sales Value, 2019-2030 5.2.2 North America Non-corticosteroid lmmunomodulators Sales Value by Country (%), 2023 VS 2030 5.3 Europe 5.3.1 Europe Non-corticosteroid lmmunomodulators Sales Value, 2019-2030 5.3.2 Europe Non-corticosteroid lmmunomodulators Sales Value by Country (%), 2023 VS 2030 5.4 Asia Pacific 5.4.1 Asia Pacific Non-corticosteroid lmmunomodulators Sales Value, 2019-2030 5.4.2 Asia Pacific Non-corticosteroid lmmunomodulators Sales Value by Country (%), 2023 VS 2030 5.5 South America 5.5.1 South America Non-corticosteroid lmmunomodulators Sales Value, 2019-2030 5.5.2 South America Non-corticosteroid lmmunomodulators Sales Value by Country (%), 2023 VS 2030 5.6 Middle East & Africa 5.6.1 Middle East & Africa Non-corticosteroid lmmunomodulators Sales Value, 2019-2030 5.6.2 Middle East & Africa Non-corticosteroid lmmunomodulators Sales Value by Country (%), 2023 VS 2030 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Non-corticosteroid lmmunomodulators Sales Value Growth Trends, 2019 VS 2023 VS 2030 6.2 Key Countries/Regions Non-corticosteroid lmmunomodulators Sales Value 6.3 United States 6.3.1 United States Non-corticosteroid lmmunomodulators Sales Value, 2019-2030 6.3.2 United States Non-corticosteroid lmmunomodulators Sales Value by Type (%), 2023 VS 2030 6.3.3 United States Non-corticosteroid lmmunomodulators Sales Value by Application, 2023 VS 2030 6.4 Europe 6.4.1 Europe Non-corticosteroid lmmunomodulators Sales Value, 2019-2030 6.4.2 Europe Non-corticosteroid lmmunomodulators Sales Value by Type (%), 2023 VS 2030 6.4.3 Europe Non-corticosteroid lmmunomodulators Sales Value by Application, 2023 VS 2030 6.5 China 6.5.1 China Non-corticosteroid lmmunomodulators Sales Value, 2019-2030 6.5.2 China Non-corticosteroid lmmunomodulators Sales Value by Type (%), 2023 VS 2030 6.5.3 China Non-corticosteroid lmmunomodulators Sales Value by Application, 2023 VS 2030 6.6 Japan 6.6.1 Japan Non-corticosteroid lmmunomodulators Sales Value, 2019-2030 6.6.2 Japan Non-corticosteroid lmmunomodulators Sales Value by Type (%), 2023 VS 2030 6.6.3 Japan Non-corticosteroid lmmunomodulators Sales Value by Application, 2023 VS 2030 6.7 South Korea 6.7.1 South Korea Non-corticosteroid lmmunomodulators Sales Value, 2019-2030 6.7.2 South Korea Non-corticosteroid lmmunomodulators Sales Value by Type (%), 2023 VS 2030 6.7.3 South Korea Non-corticosteroid lmmunomodulators Sales Value by Application, 2023 VS 2030 6.8 Southeast Asia 6.8.1 Southeast Asia Non-corticosteroid lmmunomodulators Sales Value, 2019-2030 6.8.2 Southeast Asia Non-corticosteroid lmmunomodulators Sales Value by Type (%), 2023 VS 2030 6.8.3 Southeast Asia Non-corticosteroid lmmunomodulators Sales Value by Application, 2023 VS 2030 6.9 India 6.9.1 India Non-corticosteroid lmmunomodulators Sales Value, 2019-2030 6.9.2 India Non-corticosteroid lmmunomodulators Sales Value by Type (%), 2023 VS 2030 6.9.3 India Non-corticosteroid lmmunomodulators Sales Value by Application, 2023 VS 2030 7 Company Profiles 7.1 Accord Healthcare 7.1.1 Accord Healthcare Profile 7.1.2 Accord Healthcare Main Business 7.1.3 Accord Healthcare Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.1.4 Accord Healthcare Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.1.5 Accord Healthcare Recent Developments 7.2 Bristol-Myers Squibb Company 7.2.1 Bristol-Myers Squibb Company Profile 7.2.2 Bristol-Myers Squibb Company Main Business 7.2.3 Bristol-Myers Squibb Company Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.2.4 Bristol-Myers Squibb Company Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.2.5 Bristol-Myers Squibb Company Recent Developments 7.3 Astella Pharma 7.3.1 Astella Pharma Profile 7.3.2 Astella Pharma Main Business 7.3.3 Astella Pharma Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.3.4 Astella Pharma Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.3.5 Genzyme Co. Recent Developments 7.4 Genzyme Co. 7.4.1 Genzyme Co. Profile 7.4.2 Genzyme Co. Main Business 7.4.3 Genzyme Co. Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.4.4 Genzyme Co. Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.4.5 Genzyme Co. Recent Developments 7.5 GlaxoSmithKline PLC 7.5.1 GlaxoSmithKline PLC Profile 7.5.2 GlaxoSmithKline PLC Main Business 7.5.3 GlaxoSmithKline PLC Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.5.4 GlaxoSmithKline PLC Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.5.5 GlaxoSmithKline PLC Recent Developments 7.6 Merck KGaA 7.6.1 Merck KGaA Profile 7.6.2 Merck KGaA Main Business 7.6.3 Merck KGaA Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.6.4 Merck KGaA Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.6.5 Merck KGaA Recent Developments 7.7 F.Hoffmann-La Roche AG 7.7.1 F.Hoffmann-La Roche AG Profile 7.7.2 F.Hoffmann-La Roche AG Main Business 7.7.3 F.Hoffmann-La Roche AG Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.7.4 F.Hoffmann-La Roche AG Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.7.5 F.Hoffmann-La Roche AG Recent Developments 7.8 GlenmarkPharmaceuticals, Inc. 7.8.1 GlenmarkPharmaceuticals, Inc. Profile 7.8.2 GlenmarkPharmaceuticals, Inc. Main Business 7.8.3 GlenmarkPharmaceuticals, Inc. Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.8.4 GlenmarkPharmaceuticals, Inc. Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.8.5 GlenmarkPharmaceuticals, Inc. Recent Developments 7.9 Pfizer Inc . 7.9.1 Pfizer Inc . Profile 7.9.2 Pfizer Inc . Main Business 7.9.3 Pfizer Inc . Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.9.4 Pfizer Inc . Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.9.5 Pfizer Inc . Recent Developments 7.10 Mylan Laboratories Inc. 7.10.1 Mylan Laboratories Inc. Profile 7.10.2 Mylan Laboratories Inc. Main Business 7.10.3 Mylan Laboratories Inc. Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.10.4 Mylan Laboratories Inc. Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.10.5 Mylan Laboratories Inc. Recent Developments 7.11 Actavis, Inc. 7.11.1 Actavis, Inc. Profile 7.11.2 Actavis, Inc. Main Business 7.11.3 Actavis, Inc. Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.11.4 Actavis, Inc. Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.11.5 Actavis, Inc. Recent Developments 7.12 Novartis AG 7.12.1 Novartis AG Profile 7.12.2 Novartis AG Main Business 7.12.3 Novartis AG Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.12.4 Novartis AG Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.12.5 Novartis AG Recent Developments 7.13 ydus Cadila 7.13.1 ydus Cadila Profile 7.13.2 ydus Cadila Main Business 7.13.3 ydus Cadila Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.13.4 ydus Cadila Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.13.5 ydus Cadila Recent Developments 8 Industry Chain Analysis 8.1 Non-corticosteroid lmmunomodulators Industrial Chain 8.2 Non-corticosteroid lmmunomodulators Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Non-corticosteroid lmmunomodulators Sales Model 8.5.2 Sales Channel 8.5.3 Non-corticosteroid lmmunomodulators Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer
SummaryThe global market for Non-corticosteroid lmmunomodulators was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030. Table of Contents1 Market Overview1.1 Non-corticosteroid lmmunomodulators Product Introduction 1.2 Global Non-corticosteroid lmmunomodulators Market Size Forecast 1.3 Non-corticosteroid lmmunomodulators Market Trends & Drivers 1.3.1 Non-corticosteroid lmmunomodulators Industry Trends 1.3.2 Non-corticosteroid lmmunomodulators Market Drivers & Opportunity 1.3.3 Non-corticosteroid lmmunomodulators Market Challenges 1.3.4 Non-corticosteroid lmmunomodulators Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Non-corticosteroid lmmunomodulators Players Revenue Ranking (2023) 2.2 Global Non-corticosteroid lmmunomodulators Revenue by Company (2019-2024) 2.3 Key Companies Non-corticosteroid lmmunomodulators Manufacturing Base Distribution and Headquarters 2.4 Key Companies Non-corticosteroid lmmunomodulators Product Offered 2.5 Key Companies Time to Begin Mass Production of Non-corticosteroid lmmunomodulators 2.6 Non-corticosteroid lmmunomodulators Market Competitive Analysis 2.6.1 Non-corticosteroid lmmunomodulators Market Concentration Rate (2019-2024) 2.6.2 Global 5 and 10 Largest Companies by Non-corticosteroid lmmunomodulators Revenue in 2023 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-corticosteroid lmmunomodulators as of 2023) 2.7 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Calcineurin Inhibitors 3.1.2 Antiproliferative Agents 3.1.3 mTOR Inhibitors 3.1.4 IMDH Inhibitors 3.1.5 Others 3.2 Global Non-corticosteroid lmmunomodulators Sales Value by Type 3.2.1 Global Non-corticosteroid lmmunomodulators Sales Value by Type (2019 VS 2023 VS 2030) 3.2.2 Global Non-corticosteroid lmmunomodulators Sales Value, by Type (2019-2030) 3.2.3 Global Non-corticosteroid lmmunomodulators Sales Value, by Type (%) (2019-2030) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Organ Transplant 4.1.2 Atopic Dermatitis 4.1.3 Others 4.2 Global Non-corticosteroid lmmunomodulators Sales Value by Application 4.2.1 Global Non-corticosteroid lmmunomodulators Sales Value by Application (2019 VS 2023 VS 2030) 4.2.2 Global Non-corticosteroid lmmunomodulators Sales Value, by Application (2019-2030) 4.2.3 Global Non-corticosteroid lmmunomodulators Sales Value, by Application (%) (2019-2030) 5 Segmentation by Region 5.1 Global Non-corticosteroid lmmunomodulators Sales Value by Region 5.1.1 Global Non-corticosteroid lmmunomodulators Sales Value by Region: 2019 VS 2023 VS 2030 5.1.2 Global Non-corticosteroid lmmunomodulators Sales Value by Region (2019-2024) 5.1.3 Global Non-corticosteroid lmmunomodulators Sales Value by Region (2025-2030) 5.1.4 Global Non-corticosteroid lmmunomodulators Sales Value by Region (%), (2019-2030) 5.2 North America 5.2.1 North America Non-corticosteroid lmmunomodulators Sales Value, 2019-2030 5.2.2 North America Non-corticosteroid lmmunomodulators Sales Value by Country (%), 2023 VS 2030 5.3 Europe 5.3.1 Europe Non-corticosteroid lmmunomodulators Sales Value, 2019-2030 5.3.2 Europe Non-corticosteroid lmmunomodulators Sales Value by Country (%), 2023 VS 2030 5.4 Asia Pacific 5.4.1 Asia Pacific Non-corticosteroid lmmunomodulators Sales Value, 2019-2030 5.4.2 Asia Pacific Non-corticosteroid lmmunomodulators Sales Value by Country (%), 2023 VS 2030 5.5 South America 5.5.1 South America Non-corticosteroid lmmunomodulators Sales Value, 2019-2030 5.5.2 South America Non-corticosteroid lmmunomodulators Sales Value by Country (%), 2023 VS 2030 5.6 Middle East & Africa 5.6.1 Middle East & Africa Non-corticosteroid lmmunomodulators Sales Value, 2019-2030 5.6.2 Middle East & Africa Non-corticosteroid lmmunomodulators Sales Value by Country (%), 2023 VS 2030 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Non-corticosteroid lmmunomodulators Sales Value Growth Trends, 2019 VS 2023 VS 2030 6.2 Key Countries/Regions Non-corticosteroid lmmunomodulators Sales Value 6.3 United States 6.3.1 United States Non-corticosteroid lmmunomodulators Sales Value, 2019-2030 6.3.2 United States Non-corticosteroid lmmunomodulators Sales Value by Type (%), 2023 VS 2030 6.3.3 United States Non-corticosteroid lmmunomodulators Sales Value by Application, 2023 VS 2030 6.4 Europe 6.4.1 Europe Non-corticosteroid lmmunomodulators Sales Value, 2019-2030 6.4.2 Europe Non-corticosteroid lmmunomodulators Sales Value by Type (%), 2023 VS 2030 6.4.3 Europe Non-corticosteroid lmmunomodulators Sales Value by Application, 2023 VS 2030 6.5 China 6.5.1 China Non-corticosteroid lmmunomodulators Sales Value, 2019-2030 6.5.2 China Non-corticosteroid lmmunomodulators Sales Value by Type (%), 2023 VS 2030 6.5.3 China Non-corticosteroid lmmunomodulators Sales Value by Application, 2023 VS 2030 6.6 Japan 6.6.1 Japan Non-corticosteroid lmmunomodulators Sales Value, 2019-2030 6.6.2 Japan Non-corticosteroid lmmunomodulators Sales Value by Type (%), 2023 VS 2030 6.6.3 Japan Non-corticosteroid lmmunomodulators Sales Value by Application, 2023 VS 2030 6.7 South Korea 6.7.1 South Korea Non-corticosteroid lmmunomodulators Sales Value, 2019-2030 6.7.2 South Korea Non-corticosteroid lmmunomodulators Sales Value by Type (%), 2023 VS 2030 6.7.3 South Korea Non-corticosteroid lmmunomodulators Sales Value by Application, 2023 VS 2030 6.8 Southeast Asia 6.8.1 Southeast Asia Non-corticosteroid lmmunomodulators Sales Value, 2019-2030 6.8.2 Southeast Asia Non-corticosteroid lmmunomodulators Sales Value by Type (%), 2023 VS 2030 6.8.3 Southeast Asia Non-corticosteroid lmmunomodulators Sales Value by Application, 2023 VS 2030 6.9 India 6.9.1 India Non-corticosteroid lmmunomodulators Sales Value, 2019-2030 6.9.2 India Non-corticosteroid lmmunomodulators Sales Value by Type (%), 2023 VS 2030 6.9.3 India Non-corticosteroid lmmunomodulators Sales Value by Application, 2023 VS 2030 7 Company Profiles 7.1 Accord Healthcare 7.1.1 Accord Healthcare Profile 7.1.2 Accord Healthcare Main Business 7.1.3 Accord Healthcare Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.1.4 Accord Healthcare Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.1.5 Accord Healthcare Recent Developments 7.2 Bristol-Myers Squibb Company 7.2.1 Bristol-Myers Squibb Company Profile 7.2.2 Bristol-Myers Squibb Company Main Business 7.2.3 Bristol-Myers Squibb Company Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.2.4 Bristol-Myers Squibb Company Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.2.5 Bristol-Myers Squibb Company Recent Developments 7.3 Astella Pharma 7.3.1 Astella Pharma Profile 7.3.2 Astella Pharma Main Business 7.3.3 Astella Pharma Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.3.4 Astella Pharma Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.3.5 Genzyme Co. Recent Developments 7.4 Genzyme Co. 7.4.1 Genzyme Co. Profile 7.4.2 Genzyme Co. Main Business 7.4.3 Genzyme Co. Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.4.4 Genzyme Co. Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.4.5 Genzyme Co. Recent Developments 7.5 GlaxoSmithKline PLC 7.5.1 GlaxoSmithKline PLC Profile 7.5.2 GlaxoSmithKline PLC Main Business 7.5.3 GlaxoSmithKline PLC Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.5.4 GlaxoSmithKline PLC Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.5.5 GlaxoSmithKline PLC Recent Developments 7.6 Merck KGaA 7.6.1 Merck KGaA Profile 7.6.2 Merck KGaA Main Business 7.6.3 Merck KGaA Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.6.4 Merck KGaA Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.6.5 Merck KGaA Recent Developments 7.7 F.Hoffmann-La Roche AG 7.7.1 F.Hoffmann-La Roche AG Profile 7.7.2 F.Hoffmann-La Roche AG Main Business 7.7.3 F.Hoffmann-La Roche AG Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.7.4 F.Hoffmann-La Roche AG Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.7.5 F.Hoffmann-La Roche AG Recent Developments 7.8 GlenmarkPharmaceuticals, Inc. 7.8.1 GlenmarkPharmaceuticals, Inc. Profile 7.8.2 GlenmarkPharmaceuticals, Inc. Main Business 7.8.3 GlenmarkPharmaceuticals, Inc. Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.8.4 GlenmarkPharmaceuticals, Inc. Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.8.5 GlenmarkPharmaceuticals, Inc. Recent Developments 7.9 Pfizer Inc . 7.9.1 Pfizer Inc . Profile 7.9.2 Pfizer Inc . Main Business 7.9.3 Pfizer Inc . Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.9.4 Pfizer Inc . Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.9.5 Pfizer Inc . Recent Developments 7.10 Mylan Laboratories Inc. 7.10.1 Mylan Laboratories Inc. Profile 7.10.2 Mylan Laboratories Inc. Main Business 7.10.3 Mylan Laboratories Inc. Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.10.4 Mylan Laboratories Inc. Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.10.5 Mylan Laboratories Inc. Recent Developments 7.11 Actavis, Inc. 7.11.1 Actavis, Inc. Profile 7.11.2 Actavis, Inc. Main Business 7.11.3 Actavis, Inc. Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.11.4 Actavis, Inc. Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.11.5 Actavis, Inc. Recent Developments 7.12 Novartis AG 7.12.1 Novartis AG Profile 7.12.2 Novartis AG Main Business 7.12.3 Novartis AG Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.12.4 Novartis AG Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.12.5 Novartis AG Recent Developments 7.13 ydus Cadila 7.13.1 ydus Cadila Profile 7.13.2 ydus Cadila Main Business 7.13.3 ydus Cadila Non-corticosteroid lmmunomodulators Products, Services and Solutions 7.13.4 ydus Cadila Non-corticosteroid lmmunomodulators Revenue (US$ Million) & (2019-2024) 7.13.5 ydus Cadila Recent Developments 8 Industry Chain Analysis 8.1 Non-corticosteroid lmmunomodulators Industrial Chain 8.2 Non-corticosteroid lmmunomodulators Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Non-corticosteroid lmmunomodulators Sales Model 8.5.2 Sales Channel 8.5.3 Non-corticosteroid lmmunomodulators Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療/ヘルスケア）の最新刊レポート
QYResearch社の医薬・ヘルスケア分野での最新刊レポート本レポートと同じKEY WORD（）の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|